Category NEWS

ICR and Royal Marsden Study Highlights ctDNA Testing for Early-Stage Breast Cancer Recurrence

ICR and Royal Marsden Study Highlights ctDNA Testing for Early-Stage Breast Cancer Recurrence

Personalis and Royal Marsden Study Advances Early-Stage Breast Cancer Detection with NeXT Personal® ctDNA Test ICR and Royal Marsden Study Highlights ctDNA Testing Introduction: Advancements in Breast Cancer DetectionPersonalis, Inc. has partnered with renowned researchers from The Institute of Cancer…

Read MoreICR and Royal Marsden Study Highlights ctDNA Testing for Early-Stage Breast Cancer Recurrence
Celltrion's Avtozma® (CT-P47) Biosimilar Receives European Commission Approval

Celltrion’s Avtozma® (CT-P47) Biosimilar Receives European Commission Approval

Celltrion’s Avtozma® (CT-P47) Biosimilar Receives European Commission Approval Celltrion has announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a biosimilar to RoActemra® (tocilizumab). Avtozma® is approved for all indications of its reference product, RoActemra®, including…

Read MoreCelltrion’s Avtozma® (CT-P47) Biosimilar Receives European Commission Approval
WindBorne Systems Fills Data Gaps

WindBorne Systems Fills Data Gaps as NWS Suspends Weather Balloon Launches in Alaska

WindBorne Systems Steps Up to Fill Atmospheric Data Gap After NWS Weather Balloon Suspension Introduction: NWS Suspension of Weather Balloon Launches in AlaskaThe National Weather Service (NWS) recently announced it would indefinitely suspend its weather balloon launches in Kotzebue, Alaska,…

Read MoreWindBorne Systems Fills Data Gaps as NWS Suspends Weather Balloon Launches in Alaska

Astoria Therapeutics Launches Phase 3 ALPHA-ORBIT Trial of Navenivart for HAE

Astoria Therapeutics Launches ALPHA-ORBIT Phase 3 Trial for Navenivart in Hereditary Angioedema Astoria Therapeutics, a biopharmaceutical company focused on developing breakthrough therapies for allergy and immunology disorders, has announced the initiation of the ALPHA-ORBIT trial, a pivotal Phase 3 clinical…

Read MoreAstoria Therapeutics Launches Phase 3 ALPHA-ORBIT Trial of Navenivart for HAE